CliffBio
biologic

Eylea

aflibercept

Loss of exclusivityMay 2024FDA regulatory exclusivity expiry
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameEylea
Active ingredientaflibercept
Strength2MG/0.05ML
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalNovember 2011
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Eylea patent cliff — loss of exclusivity May 2024 | CliffBio